Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium

Blood (2019) 134 (Supplement_1): 487.

https://doi.org/10.1182/blood-2019-122298

Published: 2019

Journal Articles

Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany

Stephane De Botton, Joseph M Brandwein, MD, Eytan M. Stein, MD, Andrew H. Wei, Daniela Weber, Arnaud Pigneux, Nicolas Boissel, MD PhD, Peter Paschka, MD, Konstanze Döhner, Salem Abi Nehme, Mark G. Frattini, MD, Roland Marion-Gallois, Jixian (Jason) Wang, Chris Cameron, Muhaimen Siddiqui, Rana A. Qadeer, Hartmut Döhner

Blood (2019) 134 (Supplement_1): 3893.

https://doi.org/10.1182/blood-2019-122700

Published: 2019

Journal Articles

A New Molecular Variant in the PTGS1 Gene That Abrogates Generation of Thromboxane A2 Synthesis and Associates with Platelet Dysfunction and Bleeding

Blood (2019) 134 (Supplement_1): 2375.

https://doi.org/10.1182/blood-2019-129200

Published: 2019

Journal Articles

A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation

Clara Chen, PhD BS, MS, Philippe Armand, MD PhD, Basia Rogula, Karissa Johnston, Derek Peterson, Joseph M Connors, MD, Greta Lozano-Ortega, MSc

Blood (2019) 134 (Supplement_1): 4761.

https://doi.org/10.1182/blood-2019-122302

Published: 2019

Journal Articles

Analysis of the Frequency of Spontaneous, Functionally-Significant Mutations in Genes Associated with Platelet Disorders in >120,000 Healthy Individuals

Joseph H Oved, MD BA, MA, Michele P. Lambert, MD, M. Anna Kowalska, PhD, Mortimer Poncz, MD, Konrad Karczewski, PhD

Blood (2018) 132 (Supplement 1): 2438.

https://doi.org/10.1182/blood-2018-99-115567

Published: 2018

Journal Articles

Clinical Responses of Glasdegibplus Low-Dose Ara-C, Azacitidine, and Decitabine Among Acute Myeloid Leukemia (AML) Patients Ineligible to Receive Intensive Chemotherapy: Comparative Effectiveness Using Indirect Treatment Comparison (ITC) Methods

Tracy Westley, MPH, Anna Forsythe, PharmD, MSc, MBA, Timothy J Bell, Joseph C Cappelleri, PhD MPH, MS, Gabriel Tremblay, DBA, MSc, BS, Geoffrey Chan, MD

Blood (2018) 132 (Supplement 1): 2709.

https://doi.org/10.1182/blood-2018-99-111931

Published: 2018

Journal Articles

Impact of Modified Dose Schedule of Bortezomib, Melphalan, and Prednisone (VMP) for Previously Untreated, Transplant-Ineligible Patients with Multiple Myeloma (MM): A Matching-Adjusted Indirect Comparison

Jesus F San-Miguel, MD PhD, Maria-Victoria Mateos, MD PhD, Hartmut Goldschmidt, MD, Pieter Sonneveld, MD PhD, Meletios A Dimopoulos, MD, Bart Heeg, PhD, Mahmoud Hashim, William Deraedt, Peter Hu, Annette Lam, Jianming He, PhD

Blood (2018) 132 (Supplement 1): 3553.

https://doi.org/10.1182/blood-2018-99-113157

Published: 2018

Journal Articles

Indirect Comparison Using Individual Patient Level Data Comparing Efficacy and Safety of a Daratumumab Monotherapy Vs. EU Approved Comparator Therapies in Patients with Multiple Myeloma

Irina Demmer, Susanne Huschens, Dietrich Potthoff, Jörg Tomeczkowski, Christian Englisch, Pushpike Thilakarathne, Joris Diels, Shaji K. Kumar, MD, Brian GM Durie, MD, Lewin Eisele

Blood (2018) 132 (Supplement 1): 3541.

https://doi.org/10.1182/blood-2018-99-116884

Published: 2018

Journal Articles

Comparative Effectiveness of Combination Glasdegib+ Low-Dose Cytarabine (GLAS+LDAC) Vs Combination Venetoclax + Low-Dose Cytarabine (VEN+LDAC) Among Older Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (NIC): Indirect Treatment Comparison (ITC) Methods

Tracy Westley, MPH, Anna Forsythe, PharmD, MSc, MBA, Timothy J Bell, Joseph C Cappelleri, PhD MPH, MS, Geoffrey Chan, MD, Gabriel Tremblay, DBA, MSc, BS

Blood (2018) 132 (Supplement 1): 1429.

https://doi.org/10.1182/blood-2018-99-111971

Published: 2018

Journal Articles

Identification of a Novel Heterozygous Mutation ( c.2213T>G;p.Leu738Arg ) in Platelet Glycoprotein ITGB3 gene in a Patient with Glanzmann's Thrombasthenia

Candido E. Rivera, MD, Prakash Vishnu, MD, Gretchen Schaef Johns, MD, Rajiv K. Pruthi, M.B.B.S., Dong Chen, MD PhD

Blood (2018) 132 (Supplement 1): 1158.

https://doi.org/10.1182/blood-2018-99-117995

Published: 2018

Journal Articles

The Direction of KIR Ligand Incompatibility Is Associated with Graft Failure and May Predict the Dominant Donor Following Double Umbilical Cord Blood Transplantation

Lucy Li, Merle Kolk, Kirsten Marie Boughan, DO, Paolo F Caimi, MD, Molly M Gallogly, MD PhD, Jane Little, MD, Ehsan Malek, MD, Leland Metheny, MD, Ben Tomlinson, MD, Brenda Cooper, MD, Marcos de Lima, MD, Folashade Otegbeye, MBBChir, MPH

Blood (2018) 132 (Supplement 1): 2081.

https://doi.org/10.1182/blood-2018-99-120020

Published: 2018

Journal Articles

Cost Effectiveness of Nivolumab for the Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma (cHL) after Failure of Autologous Stem Cell Transplantation (ASCT) and Treatment with Brentuximab Vedotin (BV) Treatment in Australia

Marcus Tan, BPharm, Greta Lozano-Ortega, MSc, Shelagh Szabo, MSc, Karissa Johnston, PhD, Joseph M Connors, MD, Clara Chen, PhD BS, MS, Hansoo Kim

Blood (2017) 130 (Supplement 1): 2166.

https://doi.org/10.1182/blood.V130.Suppl_1.2166.2166

Published: 2017

Journal Articles

Systemic ALK-Positive Anaplastic Large-Cell Lymphoma (ALCL): Final Analysis of an International, Individual Patient Data Study of 263 Adults

David Sibon, MD PhD, Dinh-Phong Nguyen, MD, Norbert Schmitz, MD, Ritsuro Suzuki, MD PhD, Andrew L Feldman, MD, Remy Gressin, MD, Laurence Lamant, MD PhD, Dennis D. Weisenburger, MD, Shigeo Nakamura, MD PhD, Marita Ziepert, PhD, Matthew J Maurer, MS, Martin Bast, James O. Armitage, MD, Julie M. Vose, MDMBA, Herve Tilly, Jean-Philippe Jais, MD PhD, Kerry J Savage, MD

Blood (2017) 130 (Supplement 1): 1514.

https://doi.org/10.1182/blood.V130.Suppl_1.1514.1514

Published: 2017

Journal Articles

Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients

Qian Shi, PhD, Norbert Schmitz, MD, PhD, Christopher Flowers, MD MS, Fang-Shu Ou, PhD, David Cunningham, Michael Pfreundschuh, MD, John F Seymour, Ulrich Jaeger, Thomas M. Habermann, MD, Corinne Haioun, MD PhD, Hervé Tilly, MD PhD, Herve Ghesquieres, MD PhD, Francesco Merli, Marita Ziepert, Raoul Herbrecht, MD, Jocelyne Flament, MD, Tommy Fu, PhD, Bertrand Coiffier, MD PhD, Daniel Sargent, PhD

Blood (2016) 128 (22): 4196.

https://doi.org/10.1182/blood.V128.22.4196.4196

Published: 2016

Journal Articles

Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study

Blood (2016) 128 (22): 1102.

https://doi.org/10.1182/blood.V128.22.1102.1102

Published: 2016

Journal Articles

Utility of Whole Exome Sequencing in Diagnosis of Pediatric Platelet Disorders: A Subanalysis of the Pediseq Study

Edward J Romasko, PhD, Sawona Biswas, MSc MS CGC, Batsal Devkota, PhD, Jayaraman Vijayakumar, Sowmyra Jairam, PhD, Christopher S Thom, MD PhD, Matthew C Dulik, PhD, Laura K Conlin, PhD, Nancy B. Spinner, PhD, Ian D Krantz, MD, Michele P. Lambert, MD MTR

Blood (2016) 128 (22): 3726.

https://doi.org/10.1182/blood.V128.22.3726.3726

Published: 2016

Journal Articles

A Prospective Study of Thyomosin α1 and Intravenous Immunoglobulin Role to Prevent the Infectious Pneumonia Related to Rituximab Based Immuno-Chemotherapy for B Cell Lymphoma

Tongyu Lin, Raj Shrestha Prem, He Huang, Xueying Li, Huangming Hong, Mengping Zhang, Xiaojie Fang, Zhao Wang, Chengcheng Guo, Zhongjun Xia, MD

Blood (2016) 128 (22): 5394.

https://doi.org/10.1182/blood.V128.22.5394.5394

Published: 2016

Journal Articles

Killer Cell Immunoglobulin-like Receptor Ligand Matching Determines the Post-Transplant High Risk Groups Among Patients with Permissive HLA Mismatch in Unrelated Donor Hematopoietic Cell Transplantation

Yoo Jin Lee, MD, Joon Ho Moon, MD, PhD, In Hee Lee, MD, Jae-Ho Yoon, Byung-Sik Cho, Jae-Sook Ahn, MD PhD, Hyeoung Joon Kim, MD PhD, Silvia Park, Jun Ho Jang, MD PhD, Chul Won Jung, MD PhD, Hyunsung Park, MD, June-Won Cheong, MD, Je-Hwan Lee, MD PhD, Sang Kyun Sohn, MD, PhD, Hee-Je Kim

Blood (2016) 128 (22): 4566.

https://doi.org/10.1182/blood.V128.22.4566.4566

Published: 2016

Journal Articles

Clinical Next Generation Sequencing to Identify Novel Platelet Disorders

Kathleen Freson, PhD

Blood (2016) 128 (22): SCI-38.

https://doi.org/10.1182/blood.V128.22.SCI-38.SCI-38

Published: 2016

Journal Articles

Inherited platelet disorders: toward DNA-based diagnosis

Claire Lentaigne, Kathleen Freson, Michael A. Laffan, Ernest Turro, Willem H. Ouwehand

Blood (2016) 127 (23): 2814–2823.

https://doi.org/10.1182/blood-2016-03-378588

Published: 2016

Includes: Supplemental data

NARROW

The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium

Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany

A New Molecular Variant in the PTGS1 Gene That Abrogates Generation of Thromboxane A2 Synthesis and Associates with Platelet Dysfunction and Bleeding

A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation

Analysis of the Frequency of Spontaneous, Functionally-Significant Mutations in Genes Associated with Platelet Disorders in >120,000 Healthy Individuals

Clinical Responses of Glasdegibplus Low-Dose Ara-C, Azacitidine, and Decitabine Among Acute Myeloid Leukemia (AML) Patients Ineligible to Receive Intensive Chemotherapy: Comparative Effectiveness Using Indirect Treatment Comparison (ITC) Methods

Impact of Modified Dose Schedule of Bortezomib, Melphalan, and Prednisone (VMP) for Previously Untreated, Transplant-Ineligible Patients with Multiple Myeloma (MM): A Matching-Adjusted Indirect Comparison

Indirect Comparison Using Individual Patient Level Data Comparing Efficacy and Safety of a Daratumumab Monotherapy Vs. EU Approved Comparator Therapies in Patients with Multiple Myeloma

Comparative Effectiveness of Combination Glasdegib+ Low-Dose Cytarabine (GLAS+LDAC) Vs Combination Venetoclax + Low-Dose Cytarabine (VEN+LDAC) Among Older Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (NIC): Indirect Treatment Comparison (ITC) Methods

Identification of a Novel Heterozygous Mutation ( c.2213T>G;p.Leu738Arg ) in Platelet Glycoprotein ITGB3 gene in a Patient with Glanzmann's Thrombasthenia

The Direction of KIR Ligand Incompatibility Is Associated with Graft Failure and May Predict the Dominant Donor Following Double Umbilical Cord Blood Transplantation

Cost Effectiveness of Nivolumab for the Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma (cHL) after Failure of Autologous Stem Cell Transplantation (ASCT) and Treatment with Brentuximab Vedotin (BV) Treatment in Australia

Systemic ALK-Positive Anaplastic Large-Cell Lymphoma (ALCL): Final Analysis of an International, Individual Patient Data Study of 263 Adults

Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients

Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study

Utility of Whole Exome Sequencing in Diagnosis of Pediatric Platelet Disorders: A Subanalysis of the Pediseq Study

A Prospective Study of Thyomosin α1 and Intravenous Immunoglobulin Role to Prevent the Infectious Pneumonia Related to Rituximab Based Immuno-Chemotherapy for B Cell Lymphoma

Killer Cell Immunoglobulin-like Receptor Ligand Matching Determines the Post-Transplant High Risk Groups Among Patients with Permissive HLA Mismatch in Unrelated Donor Hematopoietic Cell Transplantation

Clinical Next Generation Sequencing to Identify Novel Platelet Disorders

Inherited platelet disorders: toward DNA-based diagnosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only